This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
A CRA expert provided strategic consulting expertise regarding the suitability of various statistical tools and techniques that might be leveraged to assess the efficacy of a new pharmaceutical for a rare disease.
The CRA expert reviewed data from a variety of existing studies and analyzed limitations and opportunities regarding the use of such data. Client relied upon CRA’s analysis for business decision-making and negotiation purposes.
Under Section 337, a complainant must demonstrate that a domestic industry relating to each asserted patent either exists or is in the process of being...
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...
Our fast-paced, highly practical format ensures that you will receive a complete look at what is taking place, key trends, and expert analysis from our...
The event aims at connecting the global community of arbitration practitioners, both in person and virtually, fostering rich academic discussions and...
